Develops small molecule therapeutics targeting novel oncology and immunology pathways, with lead program ETX-19477 in Phase 1 trials for solid tumors.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Overview
858 Therapeutics is a clinical-stage biotechnology company focused on developing small molecule therapeutics targeting novel oncology and immunology pathways. Its lead program, ETX-19477, is a potent and selective inhibitor of the DNA repair protein PARG, currently undergoing Phase 1 clinical trials for patients with advanced solid tumors. The company also has preclinical assets targeting ADAR1, METTL3, and QPCT/L, aiming to address unmet needs in cancer and immune diseases.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
858 Therapeutics Management Team
858 Therapeutics Valuations & Financials
View real-time NPM data on 858 Therapeutics stock including daily 858 Therapeutics stock price estimates, valuation history, and historical share price information. Access 858 Therapeutics financing rounds, secondary trade levels, cap table data, and private company comparable transactions. Use NPM's private company valuation database to track 858 Therapeutics pricing across six independent market signals. Looking for private company due diligence data sources on 858 Therapeutics? Get in touch to learn more.
Similar Companies
like 858 Therapeutics
Color
Healthcare & Life Sciences
Physician-ordered genetic testing with comprehensive support, utilizing advanced software and a certified laboratory.
Cityblock
Healthcare & Life Sciences
Tech-driven care provider for communities with complex needs.
Elligo Health Research
Healthcare & Life Sciences
Connects healthcare sites, sponsors, and patients to streamline clinical trial access through technology and data-driven solutions.
Benchling
Healthcare & Life Sciences
Cloud based platform for research and development in biotechnology.
OpenEvidence
Healthcare & Life Sciences
Empowers clinicians who seek evidence‑based insights by delivering AI‑summarized medical research at the point of care.
Cerebral
Healthcare & Life Sciences
Telemedicine mental health startup, providing evidence-based therapeutic techniques and medication management.
Lyra
Healthcare & Life Sciences
Digital health startup using technology to connect companies and employees to mental health providers.
Resilience
Healthcare & Life Sciences
Operates as technology-focused biomanufacturing company dedicated to broadening access to complex medicines.
FAQ
We have answers
858 Therapeutics stock does not trade on public stock exchanges. 858 Therapeutics stock is considered a private security and you need to be an accredited investor to trade shares. To invest in 858 Therapeutics stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.
Learn more about the secondary market for private company shares on the investors page.
858 Therapeutics Stock does not trade on public stock exchanges. In order to sell 858 Therapeutics shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.
Learn more about NPM services for selling privately held stock on the Employee Shareholders page.
Read more about how to sell private company stock on the private secondary market:
858 Therapeutics does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the NPM Data and Intelligence database from Nasdaq Private Market, you can view 858 Therapeutics share price and other valuable private market data.
Read more about secondary market private company stock prices:
There is no ticker symbol for 858 Therapeutics stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.
Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell 858 Therapeutics stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Learn more about selling privately held stock on the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in 858 Therapeutics stock, you need to be an accredited entity or institutional investor.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
858 Therapeutics is a private company and has not had an IPO. There is currently no 858 Therapeutics IPO price. Get started to begin exploring the Nasdaq Private Market Data and Intelligence database and gain access to actionable data related to 858 Therapeutics IPO.
Learn more about Data and Intelligence private company stock data for institutional investors on the on the NPM Data and Intelligence Product Page.
